CODX vs. DRIO, MDAI, LNSR, ICU, MODD, LUCD, RVP, CTCX, ICAD, and CTSO
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include DarioHealth (DRIO), Spectral AI (MDAI), LENSAR (LNSR), SeaStar Medical (ICU), Modular Medical (MODD), Lucid Diagnostics (LUCD), Retractable Technologies (RVP), Carmell (CTCX), iCAD (ICAD), and Cytosorbents (CTSO). These companies are all part of the "surgical & medical instruments" industry.
Co-Diagnostics (NASDAQ:CODX) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
In the previous week, Co-Diagnostics had 3 more articles in the media than DarioHealth. MarketBeat recorded 5 mentions for Co-Diagnostics and 2 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.30 beat Co-Diagnostics' score of 0.20 indicating that DarioHealth is being referred to more favorably in the news media.
Co-Diagnostics has higher earnings, but lower revenue than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
DarioHealth has a net margin of -165.96% compared to Co-Diagnostics' net margin of -518.69%. Co-Diagnostics' return on equity of -35.37% beat DarioHealth's return on equity.
Co-Diagnostics has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
Co-Diagnostics currently has a consensus target price of $2.50, suggesting a potential upside of 125.23%. DarioHealth has a consensus target price of $5.37, suggesting a potential upside of 262.61%. Given DarioHealth's stronger consensus rating and higher probable upside, analysts plainly believe DarioHealth is more favorable than Co-Diagnostics.
15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 2.4% of Co-Diagnostics shares are owned by company insiders. Comparatively, 10.1% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Co-Diagnostics received 35 more outperform votes than DarioHealth when rated by MarketBeat users. However, 67.04% of users gave DarioHealth an outperform vote while only 63.49% of users gave Co-Diagnostics an outperform vote.
Summary
DarioHealth beats Co-Diagnostics on 12 of the 18 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
